These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23213667)

  • 21. Elimination of lymphatic filariasis.
    Michael E; Malecela-Lazaro MN; Kazura JW
    Lancet; 2006 Jul; 368(9533):362-3; author reply 363-4. PubMed ID: 16876654
    [No Abstract]   [Full Text] [Related]  

  • 22. Global programme to eliminate lymphatic filariasis.
    Wkly Epidemiol Rec; 2007 Oct; 82(42):361-80. PubMed ID: 17948605
    [No Abstract]   [Full Text] [Related]  

  • 23. Elimination of lymphatic filariasis: a public-health challenge.
    Zagaria N; Savioli L
    Ann Trop Med Parasitol; 2002 Dec; 96 Suppl 2():S3-13. PubMed ID: 12630389
    [No Abstract]   [Full Text] [Related]  

  • 24. Setting the stage for a Global Programme to Eliminate Lymphatic Filariasis: the first 125 years (1875-2000).
    Ottesen EA; Horton J
    Int Health; 2020 Dec; 13(Suppl 1):S3-S9. PubMed ID: 33349877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elimination of lymphatic filariasis as a public health problem.
    Cox FE
    Parasitol Today; 2000 Apr; 16(4):135. PubMed ID: 10725894
    [No Abstract]   [Full Text] [Related]  

  • 26. Progress towards eliminating lymphatic filariasis in Zanzibar: a model programme.
    Mohammed KA; Molyneux DH; Albonico M; Rio F
    Trends Parasitol; 2006 Jul; 22(7):340-4. PubMed ID: 16713740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short communication: impact of long-term (14 years) bi-annual ivermectin treatment on Wuchereria bancrofti microfilaraemia.
    Kyelem D; Medlock J; Sanou S; Bonkoungou M; Boatin B; Molyneux DH
    Trop Med Int Health; 2005 Oct; 10(10):1002-4. PubMed ID: 16185234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significant decrease in the prevalence of Wuchereria bancrofti infection in anopheline mosquitoes following the addition of albendazole to annual, ivermectin-based, mass treatments in Nigeria.
    Richards FO; Pam DD; Kal A; Gerlong GY; Onyeka J; Sambo Y; Danboyi J; Ibrahim B; Terranella A; Kumbak D; Dakul A; Lenhart A; Rakers L; Umaru J; Amadiegwu S; Withers PC; Mafuyai H; Jinadu MY; Miri ES; Eigege A
    Ann Trop Med Parasitol; 2005 Mar; 99(2):155-64. PubMed ID: 15814034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners.
    Babu BV; Nath N
    Ann Trop Med Parasitol; 2004 Oct; 98(7):751-7. PubMed ID: 15509429
    [No Abstract]   [Full Text] [Related]  

  • 30. Twelve-month longitudinal parasitological assessment of lymphatic filariasis-positive individuals: impact of a biannual treatment with ivermectin and albendazole.
    Kanamitie JN; Ahorlu CS; Otchere J; Aboagye-Antwi F; Kwansa-Bentum B; Boakye DA; Biritwum NK; Wilson MD; de Souza DK
    Trop Med Int Health; 2017 Nov; 22(11):1451-1456. PubMed ID: 28891597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis.
    Anto F; Asoala V; Anyorigiya T; Oduro A; Adjuik M; Akweongo P; Aborigo R; Bimi L; Amankwa J; Hodgson A
    Trop Med Int Health; 2011 Sep; 16(9):1112-9. PubMed ID: 21689221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery.
    Weil GJ; Jacobson JA; King JD
    Int Health; 2020 Dec; 13(Suppl 1):S60-S64. PubMed ID: 33349879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global programme to eliminate lymphatic filariasis: progress report, 2015.
    Wkly Epidemiol Rec; 2016 Sep; 91(39):441-55. PubMed ID: 27758091
    [No Abstract]   [Full Text] [Related]  

  • 34. The end of lymphatic filariasis?
    Bockarie MJ; Molyneux DH
    BMJ; 2009 May; 338():b1686. PubMed ID: 19439451
    [No Abstract]   [Full Text] [Related]  

  • 35. Global programme to eliminate lymphatic filariasis: progress report, 2016.
    Wkly Epidemiol Rec; 2017 Oct; 92(40):594-607. PubMed ID: 28984121
    [No Abstract]   [Full Text] [Related]  

  • 36. Report on active surveillance for adverse events following the use of drug co-administrations in the global programme to eliminate lymphatic filariasis.
    Wkly Epidemiol Rec; 2003 Sep; 78(36):315-7. PubMed ID: 14518107
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of 10 years of diethylcarbamazine and ivermectin mass administration on infection and transmission of lymphatic filariasis.
    Ramaiah KD; Das PK; Vanamail P; Pani SP
    Trans R Soc Trop Med Hyg; 2007 Jun; 101(6):555-63. PubMed ID: 17374389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.
    Babu BV; Kar SK
    Trop Med Int Health; 2004 Jun; 9(6):702-9. PubMed ID: 15189460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Albendazole for the control and elimination of lymphatic filariasis: systematic review.
    Critchley J; Addiss D; Ejere H; Gamble C; Garner P; Gelband H;
    Trop Med Int Health; 2005 Sep; 10(9):818-25. PubMed ID: 16135187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elimination of lymphatic filariasis: do we have the drugs to complete the job?
    Bockarie MJ; Deb RM
    Curr Opin Infect Dis; 2010 Dec; 23(6):617-20. PubMed ID: 20847694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.